Sentiss Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sentiss Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $28.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sentiss Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $28.3M Trade | TransData Nexus

Sentiss Pharma Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $28.3M Total Trade · DGFT Verified

Sentiss Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $28.3M across 6 products in 4 therapeutic categories. Based on 592 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ciprofloxacin ($8.8M), Ofloxacin ($6.3M), Levofloxacin ($4.7M).

Sentiss Pharma Private Limited — Export Portfolio & Destination Treemap

Sentiss Pharma Private Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sentiss Pharma Private Limited? — Company Overview & Market Position

Sentiss Pharma Private Limited, established on January 13, 1994, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U74899DL1994PTC056894. As of March 31, 2025, Sentiss Pharma reported an authorized capital of ₹10.00 crore and a paid-up capital of ₹5.88 crore. The company operates in the pharmaceutical manufacturing sector, focusing on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Sentiss Pharma employs approximately 689 professionals as of March 31, 2023. The company's registered office is located at 212 Ashirwad Commercial Complex, D-I Green Park, New Delhi, Delhi 110016, India.

What Does Sentiss Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ciprofloxacin$8.8M 2Ofloxacin$6.3M

Product Portfolio — Top 6 by Export Value

Sentiss Pharma Private Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ciprofloxacin	Antibiotics	$8.8M	177	2.9%	6
2	Ofloxacin	Advanced Antibiotics	$6.3M	130	2.1%	7
3	Levofloxacin	Antibiotics	$4.7M	99	6.5%	3
4	Dexamethasone	Corticosteroids	$4.5M	90	2.5%	7
5	Tobramycin	Antibiotics	$3.0M	60	7.6%	3
6	Vati	Ayurvedic & Herbal Products	$854.2K	36	3.2%	6

Sentiss Pharma Private Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $28.3M. The top category is Antibiotics (58.6% of portfolio), followed by Advanced Antibiotics (22.4%), indicating a concentrated portfolio with the top 5 products accounting for 97.0% of total export value.

Sentiss Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sentiss Pharma operates two sterile manufacturing facilities: one in India and another in Switzerland. The Indian facility is situated in Gurgaon, Haryana, and specializes in the production of ophthalmic, inhalation, and specialty pharmaceutical products. The Swiss facility, acquired through the purchase of Akorn AG, is US FDA-approved and focuses on the manufacturing of ophthalmic eye drops and ointments. These facilities are equipped with state-of-the-art technology to ensure the production of high-quality pharmaceutical formulations.

3Key Leadership

The leadership team at Sentiss Pharma includes:

Deepak Bahri: Managing Director

Canakapalli Bhaktavatasala Rao: Director

Mahesh Kumar Garg: Director

Geeta Mathur: Director

Pratik Nupendrakumar Shah: Director

Rishi Kapoor: Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sentiss Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sentiss Pharma has made significant strides in regulated markets, particularly in the United States. The acquisition of Akorn AG in Switzerland has enhanced the company's capabilities, providing access to a US FDA-approved manufacturing facility for ophthalmic products. This facility produces ophthalmic eye drops and ointments, adhering to stringent FDA standards. While specific details regarding regulatory filings and approvals in the European Union, United Kingdom, Australia, and Japan are not publicly disclosed, the company's expansion into these markets is facilitated by its adherence to international quality standards and certifications.

2Emerging Markets

Sentiss Pharma has a notable presence in emerging markets, including Russia, where it has become the largest ophthalmic company. The company's expansion into Russia is supported by its acquisition of Akorn AG, which provides a US FDA-approved manufacturing facility for ophthalmic products. Additionally, Sentiss Pharma has operations in regions such as the United States, Europe, Dubai, Russia, and Central Asia, indicating a strategic approach to penetrating diverse markets. The company's commitment to quality and regulatory compliance positions it favorably for accessing markets with WHO prequalification requirements.

3Geographic Strategy

Sentiss Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sentiss Pharma's acquisition of Akorn AG in Switzerland has provided access to a US FDA-approved manufacturing facility for ophthalmic products. This facility produces ophthalmic eye drops and ointments, adhering to stringent FDA standards. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's adherence to international quality standards and certifications indicates a commitment to regulatory compliance in the US market.

2WHO & EU GMP

Sentiss Pharma's manufacturing facilities are equipped with state-of-the-art technology to ensure the production of high-quality pharmaceutical formulations. The company's acquisition of Akorn AG in Switzerland has provided access to a US FDA-approved manufacturing facility for ophthalmic products. While specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates are not publicly disclosed, the company's expansion into regulated markets suggests adherence to international quality standards and certifications.

3CDSCO & Indian Regulatory

Sentiss Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sentiss Pharma operates in a competitive pharmaceutical market, particularly in the ophthalmic segment. While specific market share data is not publicly disclosed, the company's expansion into Russia, where it has become the largest ophthalmic company, indicates a strong competitive position in that market. The acquisition of Akorn AG in Switzerland has provided access to a US FDA-approved manufacturing facility for ophthalmic products, enhancing the company's competitive edge in the North American market. The company's operations in Europe, Dubai, Russia, and Central Asia further diversify its market presence, allowing it to compete effectively across various regions.

2Key Differentiators

Sentiss Pharma's key differentiators include its focus on ophthalmic, inhalation, and specialty pharmaceutical products, supported by a state-of-the-art R&D center in India and two sterile manufacturing facilities in India and Switzerland. The acquisition of Akorn AG has provided access to a US FDA-approved manufacturing facility for ophthalmic products, enhancing the company's capabilities in the ophthalmic segment. The company's commitment to quality and regulatory compliance positions it favorably in both regulated and emerging markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Sentiss Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sentiss Pharma has demonstrated a strong track record in the pharmaceutical industry, with a focus on ophthalmic, inhalation, and specialty products. The company's acquisition of Akorn AG in Switzerland has provided access to a US FDA-approved manufacturing facility for ophthalmic products, enhancing its capabilities in the ophthalmic segment. The company's operations in Europe, Dubai, Russia, and Central Asia further diversify its market presence. While specific export volumes and consistency are not publicly disclosed, the company's adherence to international quality standards and certifications indicates reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Sentiss Pharma as a supplier:

FDA Approval: Confirm that the manufacturing facility is registered with the US Food and Drug Administration (FDA) and that products are listed in the FDA's Drug Establishments Current Registration System (DECRS).

WHO-GMP Certification: Ensure that the manufacturing facility complies with the World Health Organization's Good Manufacturing Practice (GMP) standards.

Frequently Asked Questions — Sentiss Pharma Private Limited

How many pharmaceutical products does Sentiss Pharma Private Limited export from India?

Sentiss Pharma Private Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Ciprofloxacin ($8.8M), Ofloxacin ($6.3M), Levofloxacin ($4.7M), Dexamethasone ($4.5M), Tobramycin ($3.0M). Total export value is $28.3M.

What is Sentiss Pharma Private Limited's total pharmaceutical export value?

Sentiss Pharma Private Limited's total pharmaceutical export value is $28.3M, based on 592 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sentiss Pharma Private Limited cover?

Sentiss Pharma Private Limited exports across 4 therapeutic categories. The largest are Antibiotics (58.6%, 3 products), Advanced Antibiotics (22.4%, 1 products), Corticosteroids (15.9%, 1 products).

Get Full Sentiss Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.